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ScienceDirectCytochrome P450 enzymes (P450s) are a superfamily of
monooxygenase enzymes with enormous potential for
synthetic biology applications. Across Nature, their substrate
range is vast and exceeds that of other enzymes. The range of
different chemical transformations performed by P450s is also
substantial, and continues to expand through interrogation of
the properties of novel P450s and by protein engineering
studies. The ability of P450s to introduce oxygen atoms at
specific positions on complex molecules makes these
enzymes particularly valuable for applications in synthetic
biology. This review focuses on the enzymatic properties and
reaction mechanisms of P450 enzymes, and on recent studies
that highlight their broad applications in the production of
oxychemicals. For selected soluble bacterial P450s (notably
the high-activity P450-cytochrome P450 reductase enzyme
P450 BM3), variants with a multitude of diverse substrate
selectivities have been generated both rationally and by
random mutagenesis/directed evolution approaches. This
highlights the robustness and malleability of the P450 fold, and
the capacity of these biocatalysts to oxidise a wide range of
chemical scaffolds. This article reviews recent research on the
application of wild-type and engineered P450s in the
production of important chemicals, including pharmaceuticals
and drug metabolites, steroids and antibiotics. In addition, the
properties of unusual members of the P450 superfamily that do
not follow the canonical P450 catalytic pathway are described.
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Introduction
The cytochromes P450 (P450s or CYPs) are an enzyme
superfamily, members of which have a vast number ofCurrent Opinion in Chemical Biology 2016, 31:136–145 physiological functions in organisms from archaea and
bacteria through to man [1]. The majority of P450
enzymes are monooxygenases, catalysing the scission of
dioxygen bound to their b-type heme iron, leading to
the formation of a highly reactive ferryl iron-oxo inter-
mediate (compound I) that catalyses the insertion of an
oxygen atom into the substrate [2,3] (Figure 1). Oxida-
tion of the P450 substrate can lead to several different
chemical outcomes — including hydroxylation, epoxi-
dation, demethylation or dealkylation, sulfoxidation, N-
oxidation and decarboxylation [4]. Most P450s use
NAD(P)H-driven redox partner systems for delivery
of the two electrons required for reduction of the ferric
heme iron (enabling dioxygen binding to ferrous heme)
and for the subsequent reduction of the ferrous-oxy
(formally ferric-superoxy) species to form a ferric-per-
oxo intermediate in the catalytic cycle (Figure 1). Eu-
karyotic P450s are bound to membranes with an N-
terminal transmembrane helix, whereas prokaryotic
P450s are soluble enzymes that lack the N-terminal
membrane anchor. The majority of mammalian P450s
are attached to the endoplasmic reticulum (microsomal
P450s), although a subset involved in steroid biosyn-
thesis are linked to the inner membrane of adrenal
gland mitochondria [5]. The microsomal P450s are
reduced by NADPH-cytochrome P450 reductase
(CPR) — an FAD-binding and FMN-binding enzyme
that is also attached to the ER membrane by an N-
terminal anchor (a class II P450 redox system) [6]. The
mitochondrial P450s interact instead with a soluble
iron-sulfur protein (adrenodoxin), which sources elec-
trons from the membrane-associated FAD-binding en-
zyme NADPH-adrenodoxin reductase (a class I system)
[7]. Most of the characterized prokaryotic P450s also
use a class I redox partner system (soluble ferredoxin
reductase and ferredoxin; flavodoxins can surrogate in
certain systems), though there is considerable further
diversity in the redox partner apparatus that drives
catalysis in prokaryotic P450 enzymes, as described
further below [8,9]. The ability of P450s to perform
regioselective and often stereoselective oxidation of
their substrates  makes them attractive catalysts for
applications in synthetic biology and in the generation
of high value oxychemicals that may not be economical
to produce by synthetic chemistry. In the following
sections, the diversity of P450 chemistry is described,
and descriptions are given of how key P450 enzymes
have been engineered for improved catalytic perfor-
mance and for novel reactivity in the generation of
useful chemical products.www.sciencedirect.com
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The cytochrome P450 catalytic cycle. The canonical P450 catalytic cycle is shown with green arrows. In the resting state (the Cys–Fe3+–H2O
species in black, common to all of the cycles shown) the heme iron is low-spin, ferric with a loosely coordinated water molecule in the distal
position. Binding of substrate (RH) shifts the ferric heme iron equilibrium to the high-spin form, enabling the first electron transfer to reduce the
iron to the ferrous state. Binding of dioxygen (O2), transfer of a second electron from a redox partner, two protonation steps (to the ferric-peroxo
and ferric-hydroperoxo intermediates) involving active site amino acids, and the release of a water molecule results in the formation of the highly
reactive ferryl-oxo porphyrin cation radical species known as compound I. Abstraction of a proton from the substrate forms a protonated ferryl
intermediate (compound II) which hydroxylates the substrate radical according to the radical rebound mechanism [49]. Alternative P450 pathways
exist for certain members of the P450 enzyme superfamily. Shown with blue arrows is the pathway to nitration of a tryptophan substrate using
nitric oxide (NO) and O2, as catalysed by TxtE (CYP1048A1) from S. scabiei and other Streptomyces species in a pathway to form the phytotoxin
thaxtomin A [26]. This pathway deviates from the canonical cycle at the ferric-superoxo species; which reacts with NO rather than being further
reduced to the ferric-peroxo form. While the mechanism of tryptophan nitration is not yet resolved, one model would be that the ferric-
peroxynitrite species formed by reaction with NO could be protonated and undergo heterolytic scission to form a ferric-hydroxy (Fe3+-OH) heme
species and a nitronium (NO2)
+ ion. The nitronium ion could then react with tryptophan by electrophilic aromatic substitution to form the L-4-
nitrotryptophan product, with further protonation of the Fe3+-OH heme leading to restoration of a H2O-coordinated resting state of the P450.
www.sciencedirect.com Current Opinion in Chemical Biology 2016, 31:136–145
138 Bioinorganic chemistryP450 redox partner systems and other diverse
routes to driving P450 catalysis
For the majority of P450 enzymes in vivo, redox partner
systems are required for monooxygenase function. How-
ever, in recent years several different types of redox
partner systems have been identified to expand the class
I/class II paradigm [8,9]. Fulco’s group discovered the
first major outlier in Bacillus megaterium P450 BM3 (BM3,
CYP102A1), a natural fusion of a soluble fatty acid hy-
droxylase P450 to a soluble CPR [10]. BM3 catalyses
arachidonic acid oxidation with a reported kcat of
280 s1; substantially faster than any mammalian
P450 [11]. BM3 naturally forms a dimer, and inter-mono-
mer (CPR1 to P4502 and vice versa) electron transfer can
support catalysis [12]. Attempts to mimic BM3’s structur-
al organization by fusion of its efficient CPR module to
heterologous P450s have resulted in functional flavocy-
tochrome enzymes, but these do not yet replicate the
catalytic efficiency of BM3, likely due in part to their
failure to generate dimers that facilitate domain–domain
interactions as efficiently as in BM3, and/or to lower
stability of the fusion enzymes [8,13,14].
More recently, a novel class of bacterial P450s fused to a
NAD(P)H-dependent flavin-containing and 2Fe-2S clus-
ter-containing reductase related to phthalate dioxygenase
reductase (PDOR) was uncovered [15]. Members of this
CYP116B family were shown to catalyse oxidation of, for
example, thiocarbamate herbicides (CYP116B1) and
alkanes (CYP116B5) [16,17]. Fusions of heterologous
P450s to the CYP116B-type PDOR domain has proven
successful in various instances, presumably in part due to
these fusions being monomeric. Examples of reconstitu-
tion of catalytic activity in such fusions include a Rhodo-
coccus jostii P450 linked to the CYP116B2 PDOR,
producing an enzyme capable of N-demethylation of
the drugs imipramine and diltiazem; and a fusion of
the P450balk enzyme from the marine bacterium Alca-
nivorax borkumensis to the same reductase, generating a
catalytically self-sufficient octane hydroxylase (producing
1-octanol) [18,19]. Recent studies also used fusion of a
PDOR to an engineered mutant of Amycolatopsis orientalis
CYP105AS1 to facilitate hydroxylation of the natural
product compactin and formation of pravastatin for in-
dustrial scale production [20]. Other natural bacterial
P450 fusions to flavodoxin and ferredoxin partners are(Figure 1 Legend Continued) An alternative mechanism might involve hom
and a reactive ferryl-oxo species. In this case the ferryl-oxo heme would ab
with the NO2. However, there is no evidence to date for formation of a trans
pathway for conversion of NO to N2O catalysed by P450nor from Fusarium 
reaction does not require additional redox partners, instead deriving its elec
a heme iron-NO complex (presented here as a ferrous-NO+ form, isoelectro
protonated (using Asp393 in P450nor) to form a doubly protonated, singlet 
involves a spin-recoupling reaction in which a N–N bond is formed and a tr
N2O, resulting in the restoration of the H2O-bound, ferric resting form of the
catalysed by a number of P450s from the CYP152 family. Hydrogen peroxid
compound 0, which then continues on the canonical P450 catalytic cycle [3
Current Opinion in Chemical Biology 2016, 31:136–145 known; involved in catabolism of explosives and in sterol
demethylation, respectively [21,22]. Such enzymes still
require electron transfer from a separate NAD(P)H-de-
pendent reductase, but do simplify this class I-like appa-
ratus to a 2-component system. Fusions between P450s
and native or heterologous ferredoxin/flavodoxin proteins
have also been generated with a view to improving
electron transfer efficiency to the P450, including a recent
study in which the cineole oxidising P450cin (CYP176A1)
from Citrobacter braakii was fused to its native flavodoxin
(CinA) using peptides of different lengths. Variants were
reconstituted with NADPH/Escherichia coli flavodoxin
reductase; ultimately identifying a 10 amino acid linker
sequence as optimal through studies of the conversion of
cineole into its 2-b-hydroxy-1,8-cineole product [23].
Unusual microbial P450s and reactions
While most P450s adhere to the paradigm involving
NADPH-dependent electron transfer from redox part-
ners to the P450 heme iron, there are a number of P450
that have distinctive mechanisms. Indeed, some P450s
function without requirement for redox partners. P450nor
(CYP55A1) from the fungus Fusarium oxysporum (and
related P450s in other fungi) catalyses the reduction of
two molecules of nitric oxide (NO) to form dinitrogen
monoxide (N2O) in the final step of a respiratory pathway
in which nitrate/nitrite are converted into N2O [8
,24].
NADH is used directly, and the crystal structure of a
P450nor mutant in complex with a NADH analogue
(NAAD — nicotinic acid pyridine dinucleotide) revealed
the binding mode of the nicotinic acid ring moiety above
the heme plane, in a position suitable (with reference to
the NO-bound form) for reduction of the complex by
hydride transfer [25] (Figure 1). In the case of TxtE
(CYP1048A1) from Streptomyces scabiei (and orthologues
from other plant pathogen Streptomyces spp.), the normal
P450 catalytic cycle progresses as far as the ferric-super-
oxo intermediate, but thereafter there is binding of NO
(produced by a Streptomyces NO synthase enzyme from
the same gene cluster) and the formation of a reactive
ferric peroxynitrite intermediate that catalyses the nitra-
tion of the P450 substrate L-tryptophan to produce L-4-
nitrotryptophan in the first committed step in the pro-
duction of the phytotoxin thaxtomin A [26]. More recent
studies on TxtE have analysed the enzyme’s ability to
nitrate other molecules, and have included exploration ofolytic scission of the ferric-peroxynitrite intermediate to produce NO2
stract a hydrogen from the tryptophan substrate and enable a reaction
ient ferryl-oxo species in TxtE [26]. Shown with purple arrows is the
oxysporum in the final step of a fungal denitrification pathway. The
trons directly from NADH [50]. The reaction is proposed to proceed via
nic with the ferric-NO form), which is reduced (by NADH) and then
Fe3+-NHOH species. Further reaction with a second NO radical
ansient Fe3+-(N2O2H2) species occurs, which decomposes to release
 P450 [51,52]. Shown with a yellow arrow is the peroxygenase reaction
e is used directly to form the reactive ferric-hydroperoxo species
0,31,53,54].
www.sciencedirect.com
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well as producing nitrated derivatives of 4-fluoro-L-tryp-
tophan and 5-fluoro-L-tryptophan using TxtE fused to the
BM3 CPR domain or to a CYP116B (PDOR)-type reduc-
tase [28].
A particularly interesting group of P450 enzymes (with
potential in the biofuels area) are the P450 peroxygenases
[29]. These are P450s that have evolved to use hydrogen
peroxide (H2O2) in place of redox partner systems, with
H2O2 converting the ferric P450 form directly to the
reactive compound 0 species (Figure 1). This ‘peroxide
shunt’ mechanism is a well known, but typically ineffi-
cient, method for driving P450 catalysis, due to compet-
ing oxidative damage to heme and protein by the
peroxide [30]. The peroxygenases BSb from Bacillus
subtilis (CYP152A1) and SPa from Sphingomonas paucimo-
bilis (CYP152B1) were the first P450 peroxygenases char-
acterized — and catalyse predominantly b-hydroxylation
and exclusively a-hydroxylation of fatty acid substrates,
respectively [8,29]. However, more recent studies
showed that a novel member of this P450 class (OleT
from a Jeotgalicoccus sp., classified as CYP152L1) catalyses
mainly oxidative decarboxylation of long chain fatty acids
to produce n-1 terminal alkenes, while BSb also produced
a proportion of terminal alkene along with its major b-
hydroxylated (and minor a-hydroxylated) products. Evi-
dence for peroxide-dependent 1-pentadecene production
from palmitic acid was also produced using E. coli cells
expressing CYP152 family P450s from other bacteria
[30]. The structure of OleT in substrate-free and ara-
chidic acid (C20:0)-bound forms demonstrated how the
lipid carboxylate group binds close to the P450 heme and
suggested a mechanism for substrate decarboxylation
[31]. Other studies demonstrated that use of a heterolo-
gous class I redox partner system could also be used to
drive OleT to produce a range of different alkenes [32].
OleT and other CYP152 P450s clearly have potential
applications in production of alkenes for use as biofuels
or in fine chemical applications.
Engineering of bacterial P450 enzymes for
novel oxychemical production
A large number of bacterial P450s have been expressed
and characterized, and these enzymes have an enormous
repertoire of substrates including fatty acids, steroids,
polyketides and terpenes [33,34]. Recent studies have
sought to expand this repertoire using protein engineer-
ing of P450s. This has typically been achieved using
knowledge from P450 structure to guide rational redesign
of the P450 active site, or by random mutagenesis or
directed evolution approaches, or by a combination of
these approaches. P450 BM3 has proven a popular model
system, based on its catalytic self-sufficiency (with P450
and CPR units fused) and its high catalytic rate [1,11].
Recent examples include use of rational mutagenesis to
facilitate the binding of the gastric proton pump inhibitorwww.sciencedirect.com (PPI) drug omeprazole. The combined F87V and A82F
mutations resulted in increased active site space and in a
conformational change in the P450 to enable oxidation of
omeprazole at the 5-methyl position (Figure 4a), mim-
icking the activity of the major human omeprazole-meta-
bolising P450 CYP2C19 [35]. Subsequent work showed
that other PPI drugs (e.g. lansoprazole) were also trans-
formed to human P450-type metabolites by the same
mutants [36]. The efficient production of human drug
metabolites (for drug safety testing) is widely researched,
and other examples include BM3 mutants that can make
the human-type 40-hydroxylated and 5-hydroxylated me-
tabolites of the non-steroidal anti-inflammatory drug
diclofenac [37]. BM3 mutants (generated using both
site-directed and random mutagenesis) have also been
used to produce metabolites of 17-b-estradiol; including
2-hydroxy-b-estradiol, a product formed by human CYP1
family P450s [38]. Further examples of the exploitation of
BM3 mutants in oxychemical production are given in
Figure 2.
Other recent examples of bacterial P450s engineered
for synthetic biology applications include the fusion of
several P450s from Rhodococcus jostii RHA1 with a
PDOR module, leading to identification of catalytically
self-sufficient enzymes generating drug metabolites,
including CYP257A1 that produced N-demethylated
products of the vasodilator diltiazem and the antide-
pressant imipramine [39]. In studies towards production
of 1-butanol  from n-butane, Nebel et al. used the
Polaromonas sp. JS666 CYP153A for butane hydroxyl-
ation, and improved the 1-butanol  product yield by
introducing a G254A mutation in the P450. Further
enhancement of product yield was achieved by fusing
the mutant P450 to the P450 BM3 reductase to create a
catalytically self-sufficient enzyme. Subsequent
improvements were achieved by performing reactions
at high pressure (15 bar) in efforts to overcome the
limited aqueous solubility of n-butane [40]. P450sca-2
from Streptomyces carbophilus is an industrially important
P450 that stereo-selectively hydroxylates compactin to
form pravastatin. A functional triple fusion enzyme
(P450sca-2/Pdx/Pdr) was created using putidaredoxin/
putidaredoxin reductase partners. This construct was
used to produce more active mutants by site-directed
saturation mutagenesis focused on the substrate access
site and substrate binding pocket regions, as well as on
the proposed P450-Pdx interaction site, leading to
substantial increases in product formation in whole cell
transformations [41].
Synthetic biology applications of P450
enzymes
The P450s have diverged into a vast number of biological
catalysts that bind and oxidise substrates of widely vary-
ing size and chemical composition. As described above,
P450 substrate selectivity can be further broadened byCurrent Opinion in Chemical Biology 2016, 31:136–145
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Diverse catalytic activities of mutant and wild-type forms of P450 BM3. P450 BM3 is a natural, soluble fusion of a fatty acid hydroxylase P450 to a
cytochrome P450 reductase, and has the highest reported monooxygenase activity among the P450s [11]. Variants of P450 BM3 with novel
substrate selectivity have been produced using both rational (structure-guided) and random/directed evolution mutagenesis procedures. The figure
shows several examples of P450 BM3 mutants with novel substrate selectivity and applications in production of novel oxychemicals. (1)
Conversion of 17-b-estradiol to 2-hydroxy-17b-estradiol by BM3 mutants made using both site-directed and random mutagenesis methods. The
2-hydroxy-b-estradiol product is also a metabolite made by human CYP1A1, CYP1A2 and CYP1B1 [38]. (2) Conversion of diclofenac to 40 and 5-
hydroxy diclofenac products from members of a library of BM3 variants carrying multiple mutations. These are the same metabolites produced by
human CYP2C9 and CYP3A4 [37]. (3) Conversion of testosterone to 15-b-hydroxytestosterone using other mutants from the same library as in (2)
[37]. (4) Conversion of the terpene ()-limonene to ()-perillyl alcohol, a potential anti-tumour drug, using the A264V/A238V/L437F BM3 triple
mutant [55]. (5) Production of 9-hydroxy-b-cembrenediol or 10-hydroxy-b-cembrenediol from b-cembrenediol using F78A/I263L and L75A/V78A/
F87G mutants, respectively. The tobacco diterpene b-cembrenediol has antibacterial and antifungal properties [56]. (6) Conversion of the non-
steroidal anti-inflammatory drug maclofenamic acid to 3-OH, 4-OH and 5-OH human-type metabolites using isolates from a BM3 mutant library
[57]. (7) Hydroxylation of 1-tetralone derivatives using BM3 mutants from a directed evolution programme [58]. (8) Conversion of the gastric PPI
drugs omeprazole and esomeprazole to their 5-hydroxylated, human CYP2C19-type metabolites by the BM3 F87V/A82F double mutant [35,36].
(9) Transformation of 1-hexene to 1,2-epoxyhexane by BM3 mutants produced by saturation mutagenesis of the active site and by recombination
of beneficial mutations [59]. (10) Conversion of the sesquiterpene (+)-valencene to (+)-nootkatol and on to (+)-nootkatone using mutants of the
camphor hydroxylase P450cam (CYP101A1, for oxidation of (+)-trans-nootkatol) and wild-type P450 BM3 for production of cis-(+)-nootkatol and
trans-(+)-nootkatol, and (+)-nootkatone [60].protein engineering. Several P450s and engineered var-
iants have now been used in synthetic biology approaches
for valuable chemical production by fermentation in mi-
crobial cells. Figure 3 shows recent important examples.Current Opinion in Chemical Biology 2016, 31:136–145 Artemisinin is a sesquiterpene lactone that is a standard
antimalarial treatment worldwide. CYP71AV1 performs
three successive oxidation reactions to convert amorpha-
diene to artemisinic acid as a precursor to artemisinin in awww.sciencedirect.com
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Figure 3
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Biotechnological applications of cytochrome P450 enzymes. There are numerous examples of the exploitation of P450 enzymes in engineered
pathways for the production of important biomolecules in microorganisms. (a) The antimalarial artemisinin, a sesquiterpene lactone, is generated
chemically from artemisinic acid, which in turn is synthesised from acetyl CoA in an engineered pathway in Saccharomyces cerevisiae. The P450
CYP71AV1 from Artemisia annua is a multifunctional oxidase enzyme that catalyses key steps in hydroxylating amorphadiene to artemesinic
alcohol, and then further to the aldehyde and on to artemisinic acid [42]. (b) Morphine has been synthesised successfully from sugar feedstock
in an engineered pathway in S. cerevisiae [44]. The pathway exploits the reticuline epimerase from opium poppy, which is a multi-domain protein
consisting of the P450 CYP82Y2 fused to an aldo-keto reductase (AKR). CYP82Y2 (1,2-dehydroreticuline synthase, DRS) catalyses the conversion
of (S)-reticuline to 1,2-dehydroreticuline; and the AKR module (1,2-dehydroreticuline reductase, DRR) then converts the product to (R)-reticuline
[43]. A second P450, CYP719B1, then converts (R)-reticuline to salutaridine [44,45]. This reaction involves reorientation and twisting of the (R)-
reticuline, and an oxidative C–C bond coupling step catalysed by CYP719B1. Relevant carbon atoms are numbered according to Gesell et al. [45].
(c) The cholesterol-lowering drug pravastatin was synthesised in Penicillium chrysogenum by introduction of the genes encoding the production of
the natural product compactin. The conversion of compactin to pravastatin was achieved by also introducing an engineered form of the
Amycolatopsis orientalis P450 CYP105AS1. This form of the enzyme (P450Prava, containing five mutations) catalyses the stereo-selective
hydroxylation of compactin to form the active pravastatin rather than its inactive epimer epi-pravastatin [20]. (d) A novel biosynthetic pathway for
production of the plant flavonoid fisetin was engineered into E. coli. Fisetin has potential anti-cancer, anti-viral and other health benefits. Fisetin
was synthesised from tyrosine in a nine-step process, the last step involving an unassigned P450 from Petunia hybrida that catalyses the
conversion by hydroxylation of the flavonoid resokaempferol to fisetin [5].Saccharomyces cerevisiae fermentation. Paddon et al. then
used a singlet oxygen source to produce artemisinin
from artemisinic acid (Figure 3a) [42]. S. cerevisiae
fermentation has also been used to produce the anal-
gesic morphine. The opium poppy reticuline epimerase
is a fusion of a P450 (CYP82Y2) to an aldo-keto reduc-
tase (AKR). The CYP82Y2 transforms (S)-reticuline to
1,2-dehydroreticuline, and the AKR converts this inter-
mediate to (R)-reticuline. Another P450 (CYP719B1)www.sciencedirect.com then converts (R)-reticuline to salutaridine in a C–C
phenol coupling reaction (Figure 3b) [43,44,45]. In a
fermentation process using Penicillium chrysogenum,
genes encoding compactin production were introduced
into the strain and an esterase gene deleted to prevent
product degradation. The introduction of an engi-
neered Amycolatopsis orientalis P450 (P450Prava) facili-
tated stereoselective hydroxylation of compactin to
form the cholesterol-lowering pravastatin (Figure 3c).Current Opinion in Chemical Biology 2016, 31:136–145
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Figure 4
(a) (b)
(c) (d)
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Structures of cytochrome P450 enzymes in complex with biotechnologically important substrates. (a) The active site of the omeprazole-bound
F87V/A82F double mutant of P450 BM3 (PDB 4KEY). The omeprazole substrate is shown in yellow sticks, with the two mutated residues (A82F
and F87V) labelled with green sticks. Other active site residues important in substrate binding are shown in purple sticks with labels, and the
heme group is in red sticks. Three water molecules that interact with the substrate are seen as red spheres and the polypeptide backbone is
shown as grey ribbon [35]. (b) Diclofenac-bound CYP105D7 from Streptomyces avermitilis (PDB 4UBS). Two molecules of diclofenac are bound
and shown in green sticks. Five triethylene glycol molecules are also found bound to the protein, with one in the active site (shown in yellow
sticks). Other residues important to substrate binding are shown in light blue sticks and are labelled. The heme group is shown as red sticks with
the polypeptide backbone as grey ribbon [61]. (c) The compactin-bound mutant form of CYP105AS1 (P450Prava) from Amycolatopsis orientalis
(PDB 4OQR). The bound compactin is shown in light blue sticks, with the mutated active site residues shown as orange sticks with labels (I95T,
A180V and L236I). The heme is shown in red sticks and the polypeptide backbone as grey ribbon [20]. (d) The quinolone antibiotic aurachin RE-
bound form of P450 RauA from Rhodococcus erythropolis (PDB 3WEC). The heme is shown in red sticks with the aurachin RE substrate shown as
magenta sticks. Key residues for substrate binding are shown as blue sticks and are labelled. Other residues (shown in green and labelled) have
hydrophobic side chains that close off the substrate-binding channel from solvent, and the polypeptide backbone is shown as grey ribbon [62].X-ray crystallographic data demonstrated clearly how
engineering enabled the productive binding of com-
pactin to P450Prava (Figure 4c) [20]. A P450-depen-
dent step was also important for the final hydroxylation
step in production of the flavonol fisetin, which has
reported anti-cancer properties. The unassigned P450
hydroxylates resokaempferol to form fisetin in an E. coli
fermentation process (Figure 3d) [46].
Another successful example of the use of a P450 en-
zyme in the production of valuable compounds is the 2-
step fermentation of tyrosine to caffeic acid using a
tyrosine ammonia lyase to form p-coumaric acid. The
Rhodopseudomonas palustris CYP199A2 proved more ef-
ficient for the subsequent conversion of p-coumaric acid
to caffeic acid than did a bacterial flavoprotein 4-cou-
marate 3-hydroxylase. Caffeic acid exhibits anti-cancerCurrent Opinion in Chemical Biology 2016, 31:136–145 and antioxidant activities [47]. In a novel approach,
Wlodarczyk et al. showed that two membrane-bound
eukaryotic P450s (CYP79A1 and CYP71E1 from the
synthetic pathway for the cyanogenic glucoside dhurrin
in the grass species Sorghum bicolor) can be integrated
into the thylakoid membrane of Synechocystis sp. PCC
6803 and that light-driven photosystem I and ferredoxin
can replace a typical P450 redox partner system to
produce substantial amounts of dhurrin in the cyano-
bacterium [48].
Summary
Cytochrome P450 enzymes across Nature have an ex-
traordinarily diverse substrate range. Mutagenesis strate-
gies continue to expand this repertoire of substrates,
particularly in the case of soluble microbial P450s for
which structural data help to guide protein engineering.www.sciencedirect.com
P450 Synthetic Biology Girvan and Munro 143In an era where synthetic biology is striving to
replace synthetic chemistry for production of high-value
chemicals, P450s have a crucial role. P450s can catalyse
the specific addition of oxygen atoms at positions on
chemical scaffolds, while this can be very challenging
by traditional chemical methods. Many examples in this
review highlight the crucial roles played by P450s in
producing important molecules through microbial fer-
mentation processes, and point to further applications
for P450s in the synthesis of valuable chemicals such as
antibiotics, drug metabolites, steroids and terpenes.
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